Core Insights - Biotricity Inc. has been recognized as one of The Americas' Fastest-Growing Companies 2025 by the Financial Times, achieving a remarkable growth rate of 256.4% during challenging global conditions [1][2][3] Company Performance - The evaluation by the Financial Times, in collaboration with Statista, focused on independent companies across the Americas based on revenue growth from 2020 to 2023, amidst significant economic challenges such as the COVID-19 pandemic and supply chain disruptions [2] - Biotricity's growth is attributed to the increasing demand for smart remote monitoring solutions, addressing the needs of over 100 million Americans who face barriers to essential healthcare services [3] Innovation and Market Position - Biotricity is at the forefront of transforming healthcare with proprietary technologies that enhance continuous remote monitoring for high-risk cardiac patients, enabling medical providers to deliver faster interventions and improve patient outcomes [3] - The company's mission to revolutionize chronic care management, particularly in the cardiac sector, is gaining momentum, as highlighted by the recognition from the Financial Times [4]

Financial Data and Key Metrics Changes - Total revenue for 2024 reached $27 million, a 32.9% increase from $20.4 million in 2023, with over 110% growth compared to Q4 2023 and a 2.4% sequential increase from Q3 2024 [19][22][48] - B2B2C employers and health plans recurring revenue grew approximately 400% year-over-year, with 35% of that growth coming from organic expansion [20][22] - Pro-forma gross profit margin increased from 51% to 72%, with gross margins for the B2B2C business around 80% for the last three quarters [21][22] - Proforma operating expenses were reduced by 35% from Q1 2024 to Q4 2024, with an anticipated further 20% reduction by Q4 2025 [22][56] Business Line Data and Key Metrics Changes - The acquisition of Twill has strengthened the company's position in the industry, allowing it to support five chronic conditions under a unified brand [9][12] - The GLP-1 companion model has been instrumental in securing employer contracts, with 10 new client wins in 2024 directly tied to GLP-1 solutions [15][19] - The client renewal rate remained above 90%, indicating strong value and impact of the platform [29] Market Data and Key Metrics Changes - The healthcare industry is shifting towards whole-person digital health and vendor consolidation, with employers and health plans demanding integrated solutions [11][12] - The rise of GLP-1 therapies has created a need for long-term behavioral and lifestyle support, with employers prioritizing comprehensive solutions [13][14] Company Strategy and Development Direction - The company aims to accelerate client growth and expand its business, targeting a 50% net client growth in 2025 [23][52] - The strategy focuses on three key priorities: accelerating commercial growth, leading the market shift to whole-person digital health, and driving operational efficiencies and profitability [52][56] - The company is positioned to capitalize on the transition towards integrated multi-condition platforms that deliver better outcomes and cost efficiencies [55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive sustainable long-term growth, supported by a strong financial profile and market-leading AI-powered platform [24][48] - The company is on track for operational cash flow breakeven by the end of 2025, with a disciplined approach to expense management [22][56] Other Important Information - The company raised $25.6 million in capital in January 2025, providing a strong financial position to execute its strategy [22] - The company has a proforma cash balance of $34.5 million as of December 31, 2024 [22] Q&A Session Summary Question: What number of patients have successfully off-boarded from GLP-1 support programs? - Management indicated that they have seen a few hundred users successfully off-boarded and will present specific data in June [61][62] Question: What are the expectations for growth in 2025, particularly regarding GLP-1 programs? - Management targets to grow by more than 50 accounts in 2025, with GLP-1 expected to double in terms of accounts [64][66] Question: How significant is the role of GLP-1 treatments in the company's strategy? - Management sees GLP-1 as a major revenue driver, with expectations for significant growth in accounts related to GLP-1 solutions [95][96] Question: What are the opportunities to expand offerings through health plans? - Management confirmed ongoing discussions with health plans to expand offerings, particularly in behavioral health and cardiometabolic conditions [73][77] Question: What is the expectation for breakeven? - Management confirmed the objective of achieving operational breakeven by the end of 2025 [84]

Financial Data and Key Metrics Changes - Total revenue for 2024 reached $27 million, a 32.9% increase from $20.4 million in 2023, with over 110% growth compared to Q4 2023 and a 2.4% sequential increase from Q3 2024 [19][22][48] - B2B2C recurring revenue grew approximately 400% year-over-year, with 35% of that growth coming from organic expansion [20][22] - Pro-forma gross profit margin increased from 51% to 72%, with gross margins for the B2B2C business around 80% for the last three quarters [21][22] - Proforma operating expenses were reduced by 35% from Q1 2024 to Q4 2024, with an anticipated further 20% reduction by Q4 2025 [22][56] Business Line Data and Key Metrics Changes - The acquisition of Twill has enabled DarioHealth to support five chronic conditions under a unified brand, enhancing its position in the digital health market [9][12] - The GLP-1 companion model has been instrumental in securing new employer contracts, with 10 new client wins in 2024 directly tied to GLP-1 solutions [15][19] - Client renewal rate remained above 90%, indicating strong value and impact of the platform [29] Market Data and Key Metrics Changes - The healthcare industry is shifting towards whole-person digital health and vendor consolidation, with employers and health plans demanding integrated solutions [11][12] - The rise of GLP-1 therapies has created a demand for long-term behavioral and lifestyle support, positioning DarioHealth as a leader in this space [13][14] Company Strategy and Development Direction - DarioHealth aims to accelerate client growth and expand its business, targeting a 50% net client growth in 2025 [23][52] - The strategy focuses on three key priorities: accelerating commercial growth, leading the market shift to whole-person digital health, and driving operational efficiencies and profitability [52][56] - The company is positioned to capitalize on the transition towards integrated multi-condition platforms that deliver better outcomes and cost efficiencies [55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained revenue growth, with a strong pipeline and market demand [26][29] - The company is on track for operational cash flow breakeven by the end of 2025, with a disciplined approach to expense management [22][56] - The increasing demand for whole-person, multi-conditioned care positions DarioHealth strongly for future growth [48][56] Other Important Information - The company raised $25.6 million in capital in January 2025, providing a strong financial position to execute its strategy [22] - DarioHealth's AI-powered platform is a key differentiator, driving engagement, operational efficiency, and improved clinical and financial outcomes [18][56] Q&A Session Summary Question: What number of patients have successfully off-boarded from GLP-1 support programs? - Management indicated that they have seen a few hundred users successfully off-boarded and will present specific data in June [61][62] Question: What are the growth expectations for 2025, particularly regarding GLP-1 programs? - Management targets to grow by more than 50 accounts in 2025, with GLP-1 expected to double in terms of accounts [64][66] Question: What is the focus on health plans and opportunities for expansion? - Management confirmed that behavioral health is a priority, with plans to expand offerings in cardiometabolic conditions [77] Question: What are the expectations for health plan revenue growth in 2025? - Management did not provide specific guidance but indicated a general target of 35% growth across all channels [80] Question: Can you explain the pricing tied to results and claims-based billing? - Management elaborated on moving towards claims-based billing, allowing for better targeting and engagement, and tying payments to clinical outcomes [124][126]

Core Insights - Accolade, Inc. has partnered with Oshi Health to enhance access to specialized gastrointestinal (GI) care, emphasizing a multidisciplinary approach to improve health outcomes for individuals managing digestive health conditions [1][4] Industry Overview - GI diseases affect up to 70 million Americans annually, leading to approximately $136 billion in healthcare costs each year, highlighting the significant economic burden of these conditions [2] - The lack of timely access to comprehensive GI care results in patients waiting an average of 2-3 years for diagnosis, contributing to increased absenteeism and reduced productivity in the workforce [2] Company Insights - Oshi Health provides an integrated team of GI specialists, including advanced practice providers, registered dietitians, and licensed psychologists, to accelerate diagnosis and achieve sustainable symptom control [3] - On average, 92% of Oshi patients achieve symptom control within 10 weeks or less, indicating the effectiveness of their care model [3] - Oshi Health is in-network with major insurance plans, expanding its coverage and accessibility for patients [4] Partnership Benefits - The partnership aims to empower employees with specialized expertise and support for managing digestive health, aligning with Accolade's commitment to high-quality care [4] - Accolade's Trusted Partner Ecosystem, launched in 2019, includes 19 partners across 12 categories, enhancing the performance of digital health solutions [5]

As filed with the U.S. Securities and Exchange Commission on October 15, 2024 Registration No. 333-281319 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No.2 to (State or other jurisdiction of incorporation or organization) FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VSEE HEALTH, INC. (Exact name of registrant as specified in its charter) (Commission File Number) (I.R.S. Employer Delaware 001-41015 86-2970927 Identification Number) 980 N Federal Hwy #3 ...

As filed with the Securities and Exchange Commission on September 8, 2023 THE SECURITIES ACT OF 1933 Registration No. 333-268994 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM S-1 on FORM F-1 REGISTRATION STATEMENT UNDER If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒ If this Form is filed to register additional securities ...

As filed with the Securities and Exchange Commission on August 4, 2023 Registration No. 333-268994 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 on FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EUDA HEALTH HOLDINGS LIMITED (Exact Name of Registrant as Specified in its Charter) (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Mitchell S. Nussbaum, Esq. Tahra T. Wright, Esq. ...